scholarly journals DYNAMICS OF THE COURSE OF RETINITIS PIGMENTOSA IN A CHILD WITH MACULAR INVOLVEMENT OVER 6 YEARS.

2021 ◽  
Vol Volume 2 (Fall) ◽  
pp. 1-4
Author(s):  
Nushaba Hasan Nuri
Keyword(s):  
Retinitis Pigmentosa ◽  
Macular Oedema ◽  
Cystoid Macular Oedema ◽  
Early Progression

Purpose: The purpose of this work was to describe retinitispigmentosa involving themaculain a child with a follow-upof6years.Methods: Casereport.Results: Over 6 years, the child exhibited an expansion of thelesionareaofthecentralretina.Onopticalcoherencetomography (OCT), there is a sharp thinning of the centralregion of the retina with pathology of the photoreceptorandpigmentlayers.Conclusion: In some cases of retinitis pigmentosa, there arechangesinthemacula,characteristicofthedryformofmaculardegeneration; in other cases, there are cysts associatedwith cystoid macular oedema; and in other cases, there is amacularhole.Inourcase,therewasanatrophiclesionofthemacula,characteristicofthedryformofage-relatedmaculardegeneration. Apparently, such involvement of the macula inthe process is typical for children with early progression of thedisease.

scholarly journals Efficacy of additional topical betamethasone in persistent cystoid macular oedema after carbonic anhydrase inhibitor treatments in retinitis pigmentosa

2018 ◽  
Vol 3 (1) ◽  
pp. e000107
Author(s):  
Shohei Kitahata ◽  
Yasuhiko Hirami ◽  
Seiji Takagi ◽  
Cody Kime ◽  
Masashi Fujihara ◽  
...  
Keyword(s):  
Carbonic Anhydrase ◽  
Retinitis Pigmentosa ◽  
Macular Oedema ◽  
Medical Records ◽  
Cystoid Macular Oedema ◽  
Topical Steroids ◽  
Foveal Thickness ◽  
Central Foveal Thickness ◽  
Corrected Visual Acuity ◽  
Iop Elevation

ObjectiveWe investigated the efficacy of additional topical betamethasone in persistent cystoid macular oedema (CMO) after carbonic anhydrase inhibitors (CAIs) therapy.Methods and analysisThis retrospective cohort study included 16 eyes of 10 patients with retinitis pigmentosa (RP). All patients were previously administered CAI for at least 3 months to treat CMO secondary to RP and lacking an effective reduction (≥11%) of central foveal thickness (CFT). We administered topical 0.1% betamethasone daily in each affected eye following a preceding course of the CAI medication as a first treatment. CMO was diagnosed using spectral-domain optical coherence tomography. CFT was regarded as the average of vertical and horizontal foveal thickness. Best-corrected visual acuity (BCVA) and intraocular pressure (IOP) were obtained from patient medical records. We compared the CFT and BCVA between baseline and the average of 1–3, 5–7, 10–14 and 16–20 months period.ResultsIn treatments with brinzolamide in 14 eyes, dorzolamide in 2 eyes and bromfenac in 2 eyes, CFT effectively decreased in 12 of 16 eyes (81%). CFT decreased significantly in 1–3 months (326±102 µm; n=16; P=0.029) and 5–7 months (297±102 µm; n=12; P=0.022) compared with baseline but not within 10–14 months (271±96 µm; n=9; P=0.485) or 16–20 months (281±134 µm; n=9; P=0.289). There were no significant intergroup differences in BCVA throughout the study. Betamethasone treatment was stopped in three patients because of IOP elevation.ConclusionOur data suggested that additional betamethasone might improve treatments for persistent CMO. Topical steroids could be an alternative option for managing persistent CMO in RP.

scholarly journals Ocular abnormalities in a large Western China patient cohort with Retinitis Pigmentosa

2020 ◽  
Author(s):  
Lian Tan ◽  
Yanling Long ◽  
Ziyang Li ◽  
Xi Ying ◽  
Jiayun Ren ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Retinitis Pigmentosa ◽  
Macular Oedema ◽  
Western China ◽  
Vitreomacular Traction ◽  
Cystoid Macular Oedema ◽  
Epiretinal Membranes ◽  
Ocular Abnormalities ◽  
Vitreomacular Traction Syndrome ◽  
Macular Holes

Abstract Background: To report the prevalence of ocular abnormalities and investigate visual acuity in a large Western China cohort of retinitis pigmentosa (RP) patients.Methods: A retrospective study was performed, reviewing the medical records and ophthalmic examination reports of 2,127 eyes from 1,065 RP patients in one eye hospital. The authors investigated the prevalence of ocular abnormalities and the relationship between best corrected visual acuity (BCVA) and macular abnormalities.Results: Nyctalopia (58.2%) and blurred vision (27.1%) were the leading consultation causes. BCVA measurements in the better eyes at first clinical presentation showed that 304 patients (28.5%) were categorised as blind and 220 patients (20.7%) as low vision. The most common ocular abnormalities were cataracts (43.1%) and macular abnormalities (59.7%), including epiretinal membranes (51.1%), cystoid macular oedema (18.4%), vitreomacular traction syndrome (2.4%), macular holes (2.3%) and choroidal neovascular membranes (0.05%). Glaucoma was found in 35 eyes (1.6%). The proportions of epiretinal membranes (P = 0.001) and macular holes (P = 0.008) increased significantly with age. The proportions of vitreomacular traction syndrome (P = 0.003) and epiretinal membranes (P < 0.001) in pseudophakia and aphakia eyes were significantly higher than in eyes that had not received operations (including cataracts and clear lens). Cystoid macular oedema was significantly associated with poorer visual acuity in RP patients with clear lens (P = 0.002).Conclusion: Cataracts and macular abnormalities are common in RP patients. In the macular abnormalities, cystoid macular oedema may have a negative effect on BCVA in RP patients with clear lens.

Therapeutic effect of prolonged treatment with topical dorzolamide for cystoid macular oedema in patients with retinitis pigmentosa

2013 ◽  
Vol 97 (9) ◽  
pp. 1187-1191 ◽  
Author(s):  
Yasuhiro Ikeda ◽  
Noriko Yoshida ◽  
Shoji Notomi ◽  
Yusuke Murakami ◽  
Toshio Hisatomi ◽  
...  
Keyword(s):  
Retinitis Pigmentosa ◽  
Therapeutic Effect ◽  
Macular Oedema ◽  
Prolonged Treatment ◽  
Cystoid Macular Oedema ◽  
Topical Dorzolamide

scholarly journals Prevalence of cystoid macular oedema, epiretinal membrane and cataract in retinitis pigmentosa

2018 ◽  
Vol 103 (8) ◽  
pp. 1163-1166 ◽  
Author(s):  
Gerald Liew ◽  
Stacey Strong ◽  
Patrick Bradley ◽  
Philip Severn ◽  
Anthony T Moore ◽  
...  
Keyword(s):  
Retinitis Pigmentosa ◽  
Macular Oedema ◽  
Epiretinal Membrane ◽  
Autosomal Recessive ◽  
Autosomal Dominant ◽  
Cystoid Macular Oedema ◽  
Dominant Inheritance ◽  
Younger Age ◽  
Multivariable Analyses ◽  
Eye Clinic

Background/AimsTo report the prevalence of treatable complications (cystoid macular oedema, CME; epiretinal membrane, ERM and cataract) in patients with retinitis pigmentosa (RP).MethodsConsecutive patients with RP attending a tertiary eye clinic in 2012. Spectral domain-optical coherence tomography was used to determine presence of CME and ERM. Clinic records were reviewed to identify cataract and pseudophakia. Multivariable analyses adjusted for age, gender and other confounders.ResultsData are presented for 338 eyes from 169 patients. CME was present in 58.6% of patients and 50.9% of eyes and was bilateral in 73.7%. ERM, cataract and pseudophakia were present in 22.8%, 23.4% and 11.2% eyes, respectively. In multivariable analyses, CME was associated with younger age (OR 0.81, 95% CI 0.67 to 0.98) but not with gender. Patients with ERM and cataract/pseudophakia were less likely to also have CME (OR 0.19, 95% CI 0.09 to 0.40 and OR 0.37, 95% CI 0.16 to 0.84, respectively). CME was most prevalent in patients with autosomal-dominant inheritance (71.4%), followed by autosomal recessive/sporadic inheritance (58.9%) and least likely in persons with X linked inheritance (12.5%, p<0.001).ConclusionsThe prevalence of treatable RP complications is high and suggests it may be clinically beneficial to screen patients with RP to identify those who may benefit from current or future interventions.

scholarly journals Intravitreal Pharmacotherapy in the Treatment of Retinitis Pigmentosa-related Cystoid Macular Oedema

2017 ◽  
Vol 11 (01) ◽  
pp. 55
Author(s):  
Oya Donmez ◽  
Ali Osman Saatci ◽  
◽  
Keyword(s):  
Retinitis Pigmentosa ◽  
Macular Oedema ◽  
Laser Photocoagulation ◽  
Vitreoretinal Surgery ◽  
Cystoid Macular Oedema ◽  
Vascular Endothelial ◽  
Central Vision ◽  
Endothelial Growth Factor ◽  
Treatment Alternatives ◽  
Visual Field Constriction

Peripheral visual field constriction and night blindness are the main features of retinitis pigmentosa (RP). However, central vision is often impaired dramatically even in the early stages of the disease when macular complications such as cystoid macular oedema (CME) occur. The pathogenesis of RP-related CME is still not well explained. Therefore, several treatment alternatives such as topical, oral and systemic pharmacotherapy; laser photocoagulation and even vitreoretinal surgery are employed by the clinicians. In this review, we summarise the clinical data on intravitreal pharmacotherapeutic agents and focus mainly on the steroids and anti-vascular endothelial growth factor agents.

scholarly journals Double trouble: exudative hypertensive retinopathy in a patient with retinitis pigmentosa

2018 ◽  
pp. bcr-2018-226950
Author(s):  
Devesh Kumawat ◽  
Vinod Kumar
Keyword(s):  
Retinitis Pigmentosa ◽  
Fluorescein Angiography ◽  
Macular Oedema ◽  
Clinical Signs ◽  
Young Female ◽  
Cystoid Macular Oedema ◽  
Hypertensive Retinopathy ◽  
Hypertension Control ◽  
Hard Exudates ◽  
Careful Clinical Examination

A young female suffering from chronic kidney disease presented with retinal features suggestive of retinitis pigmentosa (RP). Cystoid intraretinal changes were noted at the macula in both eyes on optical coherence tomography. Careful clinical examination and fluorescein angiography revealed disc oedema, macular hard exudates and flower petal leakage in both eyes. A clinical diagnosis of RP with leaking cystoid macular oedema (CMO) because of hypertensive retinopathy was made. Exudation and macular oedema subsided with hypertension control and posterior sub-Tenon steroid injection. Although CMO does not typically leak on fluorescein angiography in RP, this need not always be true. Clinical signs and fluorescein angiography help in the differentiation of macular oedema when more than one aetiology may be responsible.

Sign in / Sign up

Export Citation Format

Share Document